Whistleblower: Abbott off-label TriCor scheme put patients at risk
This article was originally published in Scrip
Abbott "trained, directed, incentivized and encouraged" its sales representatives to market TriCor (fenofibrate) for unapproved uses and to "misrepresent and withhold clinical information" about the medicine's known risks and its efficacy, a former employee is charging in a whistleblower lawsuit brought against the firm, which has been joined by the federal government and 22 states and the District of Columbia.
You may also be interested in...
$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.